Literature DB >> 15586841

A randomized multicenter trial to evaluate simple utility elicitation techniques in patients with gastroesophageal reflux disease.

Holger J Schünemann1, David Armstrong, Alessio Degl'innocenti, Ingela Wiklund, Carlo A Fallone, Lisa Tanser, Sander Veldhuyzen Van Zanten, Diane Heels-Ansdell, Samer El-Dika, Naoki Chiba, Alan N Barkun, Peggy Austin, Gordon H Guyatt.   

Abstract

BACKGROUND: Despite recommendations that patients rating their own health using utility and preference measures such as the feeling thermometer (FT) and standard gamble (SG) should also rate hypothetical marker states, little evidence supports marker state use. We evaluated whether the administration of marker states improves measurement properties of the FT and SG.
METHODS: We randomized 217 patients with gastroesophageal reflux disease to complete the FT (self-administered) and SG with marker states (FT+ / SG+, n = 112) or without marker states (FT- / SG-, n = 105) before and after 4 weeks of treatment with a proton pump inhibitor, esomeprazole. Patients also completed other health-related quality of life instruments.
RESULTS: The use of marker states did not influence baseline utility scores (FT+ 0.66, FT- 0.68; SG+ 0.77, SG- 0.78, on a scale from 0 [dead] to 1.0 [full health]). Improvement after therapy was 0.21 in FT+ and 0.15 in FT- (both P < 0.001; difference between FT+ and FT- = 0.06, P = 0.02). Improvement in SG+ was 0.07 (P < 0.001) and 0.06 in SG- (P = 0.003) (difference between SG+ and SG- = 0.01, P = 0.63). Correlations with other health-related quality of life scores were generally stronger, with some statistically significant differences in correlations, for FT+ compared with FT-, but tended to be weaker for SG+ compared with SG-.
CONCLUSION: The administration of marker states improved the responsiveness and validity of the FT but not of the SG. Decisions about administering marker states should depend on whether the FT and SG is of primary interest and the importance of optimal validity and responsiveness relative to competing objectives such as efficiency.

Entities:  

Mesh:

Year:  2004        PMID: 15586841     DOI: 10.1097/00005650-200411000-00013

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  11 in total

1.  Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients.

Authors:  Karen E Bremner; George Tomlinson; Murray D Krahn
Journal:  Qual Life Res       Date:  2007-10-03       Impact factor: 4.147

2.  Do clinical marker states improve responsiveness and construct validity of the standard gamble and feeling thermometer: a randomized multi-center trial in patients with chronic respiratory disease.

Authors:  Holger J Schünemann; Roger Goldstein; M Jeffery Mador; Douglas McKim; Elisabeth Stahl; Lauren E Griffith; Ahmed M Bayoumi; Peggy Austin; Gordon H Guyatt
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

3.  Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences.

Authors:  Wojtek Wiercioch; Robby Nieuwlaat; Elie A Akl; Robert Kunkle; Kendall E Alexander; Adam Cuker; Anita Rajasekhar; Pablo Alonso-Coello; David R Anderson; Shannon M Bates; Mary Cushman; Philipp Dahm; Gordon Guyatt; Alfonso Iorio; Wendy Lim; Gary H Lyman; Saskia Middeldorp; Paul Monagle; Reem A Mustafa; Ignacio Neumann; Thomas L Ortel; Bram Rochwerg; Nancy Santesso; Sara K Vesely; Daniel M Witt; Holger J Schünemann
Journal:  Blood Adv       Date:  2020-05-26

4.  "Like No One Is Listening to Me": A Qualitative Study of Patient-Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis.

Authors:  Zoran Kvrgic; Gladys B Asiedu; Cynthia S Crowson; Jennifer L Ridgeway; John M Davis
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-09-04       Impact factor: 4.794

5.  Comparison of the construct validity and sensitivity to change of the visual analog scale and a modified rating scale as measures of patient global assessment in rheumatoid arthritis.

Authors:  Chili Lati; Lori C Guthrie; Michael M Ward
Journal:  J Rheumatol       Date:  2010-03-01       Impact factor: 4.666

6.  The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD): responsiveness to change and English language validation.

Authors:  Peter Wahlqvist; Gordon H Guyatt; David Armstrong; Alessio Degl'innocenti; Diane Heels-Ansdell; Samer El-Dika; Ingela Wiklund; Carlo A Fallone; Lisa Tanser; Sander Veldhuyzen van Zanten; Peggy Austin; Alan N Barkun; Naoki Chiba; Holger J Schünemann
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

7.  Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol.

Authors:  Pablo Alonso-Coello; Shanil Ebrahim; Gordon H Guyatt; Kari A O Tikkinen; Mark H Eckman; Ignacio Neumann; Sarah D McDonald; Elie A Akl; Shannon M Bates
Journal:  BMC Pregnancy Childbirth       Date:  2012-05-30       Impact factor: 3.007

8.  Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial.

Authors:  Dennis W Raisch; Patricia Feeney; David C Goff; K M Venkat Narayan; Patrick J O'Connor; Ping Zhang; Don G Hire; Mark D Sullivan
Journal:  Cardiovasc Diabetol       Date:  2012-07-11       Impact factor: 9.951

9.  The impact of illness in patients with moderate to severe gastro-esophageal reflux disease.

Authors:  Samer El-Dika; Gordon H Guyatt; David Armstrong; Alessio Degl'innocenti; Ingela Wiklund; Carlo A Fallone; Lisa Tanser; Sander Veldhuyzen van Zanten; Diane Heels-Ansdell; Peter Wahlqvist; Naoki Chiba; Alan N Barkun; Peggy Austin; Holger J Schünemann
Journal:  BMC Gastroenterol       Date:  2005-07-10       Impact factor: 3.067

10.  Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study.

Authors:  Pablo Alonso-Coello; Victor M Montori; Ivan Solà; Holger J Schünemann; Philipe Devereaux; Cathy Charles; Mercè Roura; M Gloria Díaz; Juan Carlos Souto; Rafael Alonso; Sven Oliver; Rafael Ruiz; Blanca Coll-Vinent; Ana Isabel Diez; Ignasi Gich; Gordon Guyatt
Journal:  BMC Health Serv Res       Date:  2008-10-27       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.